# OnCo record cimavax-egf (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/cimavax-egf/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "cimavax-egf" ;
  schema:name "CIMAvax-EGF"@en ;
  schema:alternateName "CIMAvax"@en, "EGF vaccine"@en, "rhEGF-rP64K conjugate vaccine"@en, "CIMAvax-EGF" ;
  schema:description "CIMAvax-EGF is a Cuban vaccine for advanced non-small cell lung cancer, given after chemotherapy so the body blocks a growth signal the tumour uses. Cuba registered it in 2008. In its phase III trial the survival gain was not significant by the standard test, but was by a weighted test and among patients given at least four doses. It is not approved in the United States or the European Union."@en ;
  schema:url <https://onco.cc/drugs/cimavax-egf/> ;
  schema:dateModified "2026-11-18"^^xsd:date ;
  schema:citation <https://www.cecmed.cu/registro/rcp/biologicos/cimavaxr-egf-conjugado-quimico-factor-crecimiento-epidermico-humano>, <https://doi.org/10.1158/1078-0432.CCR-15-0855>, <https://clinicaltrials.gov/study/NCT02955290> ;
  onco:status "established" ;
  onco:tag "cuba", "cancer-vaccine" ;
  onco:modality "Therapeutic cancer vaccine: recombinant human EGF conjugated to a carrier protein, with Montanide ISA 51 adjuvant, intramuscular" ;
  onco:approval "Cuba (CECMED) 2008: Advanced (stage IIIB or IV) non-small cell lung cancer" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:companies <https://onco.cc/companies/cimab/> ;
  onco:institutions <https://onco.cc/institutions/cecmed/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-rodriguez-cimavax-egf-phase3-nsclc-ccr-2016/> .
